2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity

Area of Science:

• Pharmacology
• Neuroscience
• Medicinal Chemistry

Background:

• Depression is a complex mood disorder often treated with medications targeting neurotransmitter systems.
• Imipramine receptors and the uptake of norepinephrine (NE) and serotonin (5-HT) are key targets for antidepressant drug development.

Purpose of the Study:

• To synthesize and evaluate novel 2-phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives.
• To assess the inhibitory effects of these compounds on rat brain imipramine receptor binding and NE/5-HT synaptosomal uptake.
• To investigate the potential antidepressant activity of promising compounds in rodent models.

Main Methods:

• Synthesis of 2-phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives.
• Assay of inhibition of rat brain imipramine receptor binding.
• Measurement of synaptosomal uptake of norepinephrine and serotonin.
• Evaluation in rodent models: reserpine-induced hypothermia, histamine-induced ACTH release, and rat pineal gland noradrenergic responsiveness.

Main Results:

• Highest neurotransmitter uptake inhibition observed in 2-phenyl-2-(1-hydroxycyclohexyl)dimethylethylamines with specific aryl ring substitutions (halogen or methoxy at 3- and/or 4-positions).
• Several analogues demonstrated potential antidepressant activity in rodent models.
• Acute effects in the rat pineal gland, particularly with compounds 1-[1-(3,4-dichlorophenyl)-2-(dimethylamino)ethyl]cyclohexanol (23) and 1-[2-(dimethylamino)-1)-(4-methoxyphenyl)ethyl]cyclohexanol (4), suggested a possible rapid onset of antidepressant action.

Conclusions:

• Specific 2-phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives exhibit significant potential as antidepressants.
• Compound 4 (venlafaxine) demonstrated promising activity and is currently in clinical evaluation.
• The study provides a basis for developing new antidepressants targeting NE and 5-HT pathways.